July 19, 2010

Johns Hopkins Medicine adds four to its board of trustees

Four leaders in the financial, pharmaceutical and medical fields have been selected for one-year terms on the board of trustees of Johns Hopkins Medicine. One has also been named to a three-year term on the board of trustees of The Johns Hopkins Hospital. The new members, who began their terms July 1, are N. Anthony Coles, David C. Hodgson, Christopher W. Kersey and Barry S. Strauch.

Coles was named president, chief executive officer and member of the board of directors of Onyx Pharmaceuticals in March 2008. Previously, he held the same posts at NPS Pharmaceuticals. A graduate of Johns Hopkins, he received his medical degree from Duke University and a master’s in public health from Harvard. Coles currently serves as a member of the boards of trustees of The Johns Hopkins University and of Boston Medical Center.

Hodgson is a managing director of General Atlantic, a global growth equity firm. He graduated summa cum laude and Phi Beta Kappa from Dartmouth College with a degree in mathematics and social sciences and received an MBA from Stanford University. He is a member of the board of trustees of The Johns Hopkins University and a member of the board of advisers of Johns Hopkins Medicine.

Kersey is a managing member and partner of Camden Partners, a private equity and investment management fund, where he focuses on growth equity investments in the health care and life science industries. A graduate of Stanford, he received an MBA from Harvard and a medical degree from Emory. He also has been selected to join the board of trustees of The Johns Hopkins Hospital.

Strauch has served for the past four years as interim chairman of the Department of Medicine at Inova Fairfax Hospital, where he was chief of the Nephrology Section for 24 years. Strauch received both his undergraduate and medical degrees from Johns Hopkins and completed training in internal medicine and metabolism at Yale University and the National Institutes of Health. Strauch then became a full-time faculty member of the Yale Medical School. He was a co-founder and chairman of Washington Nephrology Associates, one of the two largest nephrology practices in the United States. He also served as chairman of a quasi-government agency that regulates quality and need for dialysis and transplantation. He currently has faculty appointments at Georgetown, George Washington and VCU medical schools.